Glaxo hires key scientists to boost imaging work
LONDON (Reuters) – GlaxoSmithKline Plc has lured three
leading scientists from academia to boost its imaging
programme, in a move underlining the growing role of clinical
imaging in the development of new drugs.
Glaxo, alongside rivals such as Pfizer Inc which is also
investing heavily in the area, hopes a better understanding of
how drugs work inside the body will a speed development and
reduce the industry’s notoriously high rate of product failure.
Much of Glaxo’s imaging work will be centred at Imperial
College’s Hammersmith Hospital campus in London, where the
British-based group is investing 46 million pounds in a new
center for magnetic resonance imaging, positron emission
tomography and optical imaging.
Imperial College and Britain’s Medical Research Council are
also plowing 20 million and 9 million pounds respectively into
the London center.
Paul Matthews, from the University of Oxford, will head up
the new clinical-imaging center, when it opens next year and
coordinate academic imaging collaborations worldwide.
Ed Bullmore, of Cambridge University, has been appointed
vice president of experimental medicine and will head the
Addenbrooke’s Center for Clinical Investigation in Cambridge,
while Marc Laruelle, from Columbia University College of
Physicians and Surgeons, has been appointed vice president for
clinical molecular imaging.